Saturday, April 26, 2025

PER-001 INTRAVITREAL IMPLANT

 


Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. Multiple lines of evidence implicate vascular dysregulation as a driver of glaucomatous disease progression, and excess endothelin levels play a key role in reducing ocular blood flow.

PER-001 is a small molecular endothelin 1 receptor antagonist administered as a bio-erodible intravitreal implant. It is being evaluated for treating open-angle glaucoma and other ocular indications driven by ischemia, such as diabetic retinopathy, geographic atrophy, and retinal vein occlusion. It is administered into the vitreous using a single-use, 25-gauge applicator. It is designed to provide a sustained release of PER-001, allowing for a convenient every 6 months dosing frequency.

The intended treatment is pursuing both vascular benefits, such as improved autoregulation and perfusion by targeting the entire retinal vasculature and choroid, as well as non-vascular benefits, such as blocking ET-1-mediated “neurotoxicity” involving apoptotic and oxidative injury pathways in the neuroretina.

Perfuse Therapeutics, Inc. (“Perfuse Therapeutics”), a biopharmaceutical company, announced the details of PER-001. Data from three cohorts of patients with glaucoma in the completed Phase 1/2a clinical trial demonstrate that PER-001 is well tolerated and shows promise as the first disease-modifying therapy for glaucoma. A study in rabbit and monkey eyes demonstrated controllable biodegradation and sustainability of the implant without any ocular or systemic adverse findings for up to 3 and 6 months in rabbits and non-human primates, respectively.

https://perfusetherapeutics.com/perfuse-therapeutics-announces-oral-presentation-on-per-001-intravitreal-implant-for-glaucoma-at-the-association-for-research-in-vision-and-ophthalmology-arvo-meeting/


No comments:

Post a Comment

ESNOPER CLIP

  Drainage implants act as flow controllers, space maintainers, and healing modulators, reducing the risk of scleral fibrosis. The suprach...